76 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
RSS Create an RSS feed from your search for:
myeloma AND (women OR woman OR female)
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Stem Cell Transplantation in Individuals With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Tandem Autologous Transplant;   Drug: Autologous Transplant Plus Non-Myeloablative Allogeneic Transplant
2 Active, not recruiting Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Dendritic Cell Tumor Fusion
3 Active, not recruiting Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone;   Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles;   Drug: Melphalan, Prednisone and Thalidomide
4 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
5 Active, not recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
6 Terminated A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: 5.0g SRT501;   Drug: Bortezomib
7 Active, not recruiting Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up
8 Active, not recruiting Agriculture Health Study
Conditions: Prostate Cancer;   Pesticide Exposure;   Lymphoma;   Multiple Myeloma
Intervention:
9 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
10 Completed S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
Conditions: Multiple Myeloma;   Smoldering Myeloma;   Waldenstrom's Macroglobulinemia;   Monoclonal Gammopathy of Undetermined Significance;   Amyloidosis
Intervention: Other: biologic sample preservation procedure
11 Recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
12 Completed Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone;   Drug: thalidomide
13 Active, not recruiting Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone
14 Not yet recruiting Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition: Multiple Myeloma
Interventions: Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo
15 Active, not recruiting Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Conditions: Breast Adenocarcinoma;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   Metastatic Malignant Neoplasm to the Bone;   Pain;   Musculoskeletal Complication;   Urinary Complications
Intervention: Drug: zoledronic acid
16 Recruiting S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
17 Recruiting Busulfan and Melphalan Conditioning in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: BUSULFEX®;   Drug: Alkeran®
18 Active, not recruiting
Has Results
Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Other: placebo;   Procedure: peripheral blood stem cell transplantation;   Drug: melphalan;   Drug: cyclophosphamide;   Biological: filgrastim
19 Active, not recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
20 Terminated
Has Results
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Condition: Refractory Multiple Myeloma
Interventions: Drug: liposomal doxorubicin;   Drug: bortezomib;   Drug: dexamethasone;   Drug: cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years